Retatrutide for type 2 diabetes: what TRANSCEND-T2D-1 found

A trial built around blood sugar, not the scale

Retatrutide's reputation was made in obesity trials. TRIUMPH-1 put the 12mg dose at 28.3% mean weight loss over 80 weeks, the largest number any Phase 3 obesity drug has recorded. But retatrutide is a triple hormone receptor agonist, GLP-1, GIP, and glucagon, and the third receptor raised a real question early on: does adding glucagon, a hormone whose main job is raising blood sugar, work against glycemic control in people who already have diabetes?

TRANSCEND-T2D-1 is the trial built to answer that. Eli Lilly enrolled 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone, none of them on other glucose-lowering medication, with a mean baseline A1C of 7.9% and an average diabetes duration of 2.5 years. That is a relatively early-stage, mild population, which matters for reading the results correctly later on. Over 40 weeks, participants took 4mg, 9mg, or 12mg of retatrutide, or a placebo.

Retatrutide type 2 diabetes results: the A1C numbers

A1C dropped 1.7 percentage points on the 4mg dose, 2.0 points on 9mg, and 1.9 points on 12mg. Placebo moved 0.8 points, mostly from the diet and exercise counseling every participant received regardless of arm. The gap between drug and placebo held across all three doses, and none of it plateaued cleanly by dose, the 9mg arm actually edged out 12mg slightly, a pattern Lilly has not fully explained but that shows up in trial noise this size.

The target numbers matter as much as the average. Between 82% and 90% of retatrutide-treated participants got their A1C below 7%, the general goal the American Diabetes Association sets for most adults. Between 75% and 85% got to 6.5% or lower, a tighter target usually reserved for people who can hit it without much hypoglycemia risk. Getting most of a trial arm under 7% in 40 weeks, without insulin or a second drug, is a strong showing by any current diabetes-drug standard.

Weight loss came along with it

Because retatrutide is dosed the same way for diabetes and obesity, the weight loss showed up too. The 4mg arm lost 11.5% of body weight, 9mg lost 15.5%, and 12mg lost 16.8%, about 36.6 lbs on average. Placebo lost 2.5%. For a population managing diabetes, not chasing a weight-loss number specifically, that is a meaningful secondary benefit, less joint load, less insulin resistance, and knock-on improvements the trial also picked up in non-HDL cholesterol, triglycerides, and systolic blood pressure.

Side effects rose with dose, as expected

The safety profile tracked what earlier retatrutide trials already showed. Nausea affected 16.4% of the 4mg group and climbed to 26.5% at 12mg. Diarrhea ran from 18.7% to 26.3%, and vomiting from 15.0% to 17.6%. All three sat well above the 3-5% range seen on placebo. A smaller share of participants, 2.3% to 4.5%, reported dysesthesia, an unpleasant tingling or prickling sensation, which showed up in zero placebo patients. None of this is new: it is the same GI-heavy profile documented in retatrutide's obesity trials. What is worth noting is that discontinuation from side effects stayed low, 2.2% to 5.1% depending on dose, versus zero on placebo, suggesting most of the GI burden was tolerable enough that people stayed on the drug.

How this stacks up against tirzepatide

The obvious comparison is tirzepatide, already FDA-approved for type 2 diabetes as Mounjaro. In SURPASS-2, published in the New England Journal of Medicine, tirzepatide's 15mg dose cut A1C by 2.30 points over the same 40-week window. On paper, that beats retatrutide's best result of 2.0 points.

The populations are not the same trial, though, and the gap is not a fair head-to-head. SURPASS-2 enrolled 1,879 people with a mean diabetes duration of 8.6 years, already on metformin, with a higher average starting A1C. TRANSCEND-T2D-1 enrolled people 2.5 years into diagnosis, on diet and exercise alone, with a lower baseline A1C of 7.9%. A milder, earlier population generally has less room to drop, since there is less elevated blood sugar to correct in the first place. Comparing the two numbers side by side is informative, not conclusive. Lilly has not run retatrutide against tirzepatide in a matched diabetes population, the way TRIUMPH-1 and SURMOUNT-1 get compared for obesity.

Where retatrutide stands for diabetes right now

The diabetes result matters beyond its own numbers. It closes off a real concern: that activating the glucagon receptor, on top of GLP-1 and GIP, might work against glycemic control in people who already struggle to regulate blood sugar. It did not. That clears one of the last open questions standing between retatrutide and a broad NDA filing that covers both obesity and diabetes at once.

What this means if you have type 2 diabetes today

Nothing changes yet for people managing diabetes right now. Tirzepatide is approved, available, and backed by five years of SURPASS trial data plus real-world prescribing history. Retatrutide is a promising Phase 3 readout, not a treatment option outside a trial. If your A1C is not at target on your current regimen, that is a conversation for your prescriber today, not a reason to wait a year and a half for a drug that has not finished review.

For people already tracking the obesity side of retatrutide's data, this trial is the missing half of the picture, the full mechanism and TRIUMPH-1 breakdown is here. For a look at how another combination drug performed in the same diabetes population, see CagriSema's REIMAGINE results.